Johnson & Johnson Reportedly Considering $10 Billion Acquisition of CNS-Focused Intra-Cellular Therapies

According to Bloomberg,Johnson & Johnson Is Considering Acquiring CNS Pharma Manufacturer Intra-Cellular Therapies。The two parties may reach an agreement as early as this week.According toValuation,Intra-Cellular's market value is approximately 10 billion US dollars.

Intra-Cellular Therapies, founded in 2002, is a company focused onDevelopment and Commercialization of Therapies for Central Nervous System (CNS) DiseasesBiopharmaceutical company, the company completed in April 2024$575 millionThe initial public offering (IPO) demonstrates its strong performance in the capital market and future development potential.

Intra-Cellular TherapiesThe first proprietary product, Caplyta, is used to treat acute schizophrenia.Compared with the same period in 2023, Caplyta's sales in the third quarter of 2024Increased by 39%, reaching 175 million U.S. dollars.

Products with faster progress in the pipelineLumateperone Submitted for Regulatory Approval, intended for the treatment of bipolar disorder and behavioral symptoms associated with dementia (including Alzheimer's disease).

Intra-Cellular Therapies Pipeline

Reportedly, the negotiations are still in the early stages, and no final decision has been made.Sources said that the negotiations cannot guarantee a formal agreement, and other potential buyers may emerge.

Friday, Intra-Cellular Shares SoaredNearly 15%, reflecting investors' expectations for potential transactions.

Johnson & Johnson has been actively expanding into high-growth therapeutic areas to solidify the growth of its pharmaceutical division amidst increasing competition. This potential acquisition could help Johnson & Johnson broaden its neuroscience portfolio and offset revenue challenges posed by the expiration of patents on its blockbuster drugs.

The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance regarding any statements or viewpoints expressed and does not provide any explicit or implicit guarantees concerning the accuracy, reliability, or completeness of the content. Readers are advised to use the information as a reference only and assume full responsibility for their actions. The various articles published by this WeChat Official Account aim to share information; if there is any infringement, please contact us, and we will delete the content.

(Reposted from: Qiu Shi Pharmacy)